Can-Fite BioPharma Ltd. (CANF)
AMEX: CANF
· Real-Time Price · USD
1.05
-0.03 (-2.78%)
At close: Jun 13, 2025, 3:59 PM
1.05
0.00%
After-hours: Jun 13, 2025, 07:55 PM EDT
-2.78% (1D)
| Bid | 1.02 |
| Market Cap | 13.52M |
| Revenue (ttm) | 674K |
| Net Income (ttm) | -7.88M |
| EPS (ttm) | -2.6 |
| PE Ratio (ttm) | -0.4 |
| Forward PE | -35.83 |
| Analyst | Buy |
| Ask | 1.1 |
| Volume | 38,840 |
| Avg. Volume (20D) | 282,714 |
| Open | 1.08 |
| Previous Close | 1.08 |
| Day's Range | 1.05 - 1.08 |
| 52-Week Range | 0.98 - 4.69 |
| Beta | 0.23 |
About CANF
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CANF
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CANF stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-19.31%
Can-Fite Biopharma shares are trading lower. The c...
Unlock content with
Pro Subscription
3 months ago
+22.42%
Can-Fite Biopharma shares are trading higher after the company received FDA approval for compassionate use of its namodenoson for pancreatic cancer.
